Rathbone Brothers plc Has $137,000 Stake in Aratana Therapeutics, Inc. (PETX)

Rathbone Brothers plc continued to hold its position in shares of Aratana Therapeutics, Inc. (NASDAQ:PETX) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 18,900 shares of the biopharmaceutical company’s stock at the end of the second quarter. Rathbone Brothers plc’s holdings in Aratana Therapeutics were worth $137,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Ray Gerald L & Associates Ltd. raised its stake in shares of Aratana Therapeutics by 0.8% during the 2nd quarter. Ray Gerald L & Associates Ltd. now owns 24,100 shares of the biopharmaceutical company’s stock worth $174,000 after buying an additional 200 shares during the last quarter. Janney Montgomery Scott LLC raised its stake in shares of Aratana Therapeutics by 7.9% during the 2nd quarter. Janney Montgomery Scott LLC now owns 16,400 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 1,200 shares during the last quarter. American International Group Inc. raised its stake in shares of Aratana Therapeutics by 7.1% during the 1st quarter. American International Group Inc. now owns 20,534 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 1,354 shares during the last quarter. Geneva Advisors LLC raised its stake in shares of Aratana Therapeutics by 3.7% during the 2nd quarter. Geneva Advisors LLC now owns 80,118 shares of the biopharmaceutical company’s stock worth $579,000 after buying an additional 2,830 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY raised its stake in shares of Aratana Therapeutics by 17.9% during the 1st quarter. Metropolitan Life Insurance Co. NY now owns 25,619 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 3,883 shares during the last quarter. 73.07% of the stock is owned by institutional investors and hedge funds.

Several research firms have recently issued reports on PETX. BidaskClub downgraded Aratana Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. ValuEngine raised Aratana Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 25th. Jefferies Group LLC reaffirmed a “buy” rating and set a $8.00 price target on shares of Aratana Therapeutics in a research note on Sunday, May 14th. Lake Street Capital cut their price target on Aratana Therapeutics from $15.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, August 25th. Finally, Zacks Investment Research downgraded Aratana Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 13th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $8.25.

COPYRIGHT VIOLATION WARNING: “Rathbone Brothers plc Has $137,000 Stake in Aratana Therapeutics, Inc. (PETX)” was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://sportsperspectives.com/2017/09/10/rathbone-brothers-plc-has-137000-stake-in-aratana-therapeutics-inc-petx.html.

Aratana Therapeutics, Inc. (NASDAQ:PETX) opened at 5.83 on Friday. The company has a 50-day moving average of $6.05 and a 200 day moving average of $6.20. The firm’s market cap is $250.70 million. Aratana Therapeutics, Inc. has a 52 week low of $4.97 and a 52 week high of $10.73.

Aratana Therapeutics (NASDAQ:PETX) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.03. Aratana Therapeutics had a negative return on equity of 51.21% and a negative net margin of 642.93%. The business had revenue of $5.16 million during the quarter, compared to the consensus estimate of $4.50 million. During the same period in the prior year, the business posted $0.61 earnings per share. Aratana Therapeutics’s revenue was down 86.4% compared to the same quarter last year. On average, equities analysts predict that Aratana Therapeutics, Inc. will post ($1.09) earnings per share for the current year.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Want to see what other hedge funds are holding PETX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aratana Therapeutics, Inc. (NASDAQ:PETX).

Institutional Ownership by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply